Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar

Inclusion Criteria

• •1. Any sex; age 18-70 years.
• •2. Histologically confirmed non-keratinizing nasopharyngeal carcinoma (World Health Organization (WHO) type II or III).
• •3. Clinical stage I-IVA (American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) 8th edition) with no evidence of distant metastasis.
• •4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
• •5. No prior anti-tumor treatment for nasopharyngeal carcinoma, including radiotherapy, chemotherapy, immunotherapy, or biologic therapy.
• •6. No contraindications to radiotherapy or chemotherapy.
• •7. Adequate major organ function as defined below:
• •7.1 Hematology: white blood cell (WBC) ≥ 4.0 × 10\^9/L, absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L, platelet count ≥ 100 × 10\^9/L, hemoglobin ≥ 90 g/L (no blood transfusion or blood products within 14 days and no use of granulocyte colony-stimulating factor (G-CSF) or other hematopoietic growth factors to correct counts);
• •7.2 Biochemistry: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN); blood urea nitrogen (BUN) and serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 60 mL/min calculated by the Cockcroft-Gault formula.
• •8. Participant voluntarily agrees to join the study, signs informed consent, has good compliance, and is able to attend follow-up.